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Abstract MicroRNAs (miRNAs) regulate gene expres-
sion through degradation and/or translational repression of
target mRNAs. Dysregulations in the miRNA machinery
may be involved in carcinogenesis of colorectal cancer
(CRC). The purpose of the current study was to evaluate
the DiGeorge syndrome critical region gene 8 (DGCR8)
and argonaute 2 (AGO2) mRNA expression in CRC and to
evaluate the value of clinical parameters on their expres-
sion. We investigated the mRNA expressions of DGCR8
and AGO2 in 60 CRC tissues and adjacent histologically
non-neoplastic tissues by using quantitative real-time PCR.
Our study revealed that the mRNA expression level of
DGCR8 is up-regulated in CRC. However, AGO2 mRNA
expression was not significantly altered in CRC tissues.
Neither DGCR8 nor AGO2 mRNA expression level was
not associated with any clinical parameters, including age,
tumor stage, CEA titer, and BMI in CRC cases. However,
the mRNA expression levels of DGCR8 and AGO2 were
positively correlated to each other. This study demon-
strated for the first time that the DGCR8 mRNA expression
level was up-regulated in CRC, suggesting its important
role in pathobiology of colorectal carcinogenesis.
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Introduction
Colorectal cancer (CRC) is a malignant tumor that origi-
nates from the epithelium of colon and rectum and the third
most common incident cancer among men worldwide [1].
It has been reported that the five leading primary cancer
sites were the stomach, colon and rectum, lung, liver, and
prostate in male during 2009 in Korea [2]. In Korea, annual
percentage changes of CRC incidence in age-standardized
incidence rates were 6.8 % in men between 1999 and 2009
using the world standard population as a standard popula-
tion [2]. The pathogenesis of CRC is intricate and tightly
regulated mechanisms, which involve the accumulation of
both genetic and epigenetic alterations in the proliferating
cells [3].
In recent years, gradually accumulating evidences have
demonstrated that a wide range of biological processes
such as cellular development, differentiation, proliferation,
cell death, metabolism, and carcinogenesis are associated
with a group of endogenous, small (approximately 17
nucleotides), and noncoding RNAs called microRNAs
(miRNAs) [4–6]. The biogenesis of miRNA occurs in a
well-organized process, referred to as the ‘‘miRNA
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machinery’’ [7]. The microprocessor complex mediates
intranuclear biogenesis of precursor miRNAs from the
primary miRNA transcript. Extranuclear, mature miRNAs
are incorporated into the RNA-induced silencing complex
(RISC) before interaction with complementary target
mRNA that leads to protein translational repression or
mRNA destabilization [8, 9]. The DiGeorge syndrome
critical region gene 8 (DGCR8) is a part of microprocessor
complex and has been shown to be essential for miRNA
maturing [10]. The argonaute 2 (AGO2) protein is a con-
stituent of a complex protein designated as RISC [11].
Previous study has demonstrated that DGCR8 mRNA
expression level is down-regulated in prostate cancer [12].
Up-regulated mRNA expression level of DGCR8 has been
revealed in epithelial skin cancer [8] and pleomorphic
adenomas of the salivary gland [13]. It has been reported
that the AGO2 mRNA expression level is up-regulated in
epithelial skin cancer [8]. Though Papachristou et al. [7]
studied the mRNA expression levels of Dicer, Drosha, and
AGO2 in CRCs, there are little literatures about the mRNA
expression level of DGCR8 and clinicopathologic associ-
ation in the cancers.
In the present study, we aimed to investigate the mRNA
expression levels of DGCR8 and AGO2 in human CRC
tissues and corresponding adjacent non-neoplastic tissues
from male patients with same cancer, and examined the
correlation of the mRNA levels of these miRNA machinery
components with various clinicopathologic parameters,
including age, tumor stage, BMI, and CEA titer.
Materials and methods
Patients and tissues
Altogether, sixty male patients diagnosed with CRC were
included in the study. Colorectal adenocarcinomas and
adjacent non-neoplastic tissues were obtained from the
patients undergoing surgery in Dongsan Medical Center
(Daegu, Korea) between April 2008 and January 2010.
Tissue samples were immediately frozen in liquid nitrogen
and stored at -80 C until RNA isolation. Tissue samples
were provided from Keimyung Human Bio-resource Bank,
Korea. All patients were explained the study purpose, and
informed consent was obtained from each study partici-
pant. The protocols were approved by the Institutional
Review Board of Keimyung University Dongsan Medical
Center (approval #12–41).
RNA and quantitative real-time PCR
Total cellular RNA was extracted from tissues using the
TRIzol reagent (Molecular Research Center Inc.,
Cincinnati, OH, USA). RNA was quantified using Nano-
drop 1000 (Thermo Scientific, Wilmington, Denmark).
Each cDNA was synthesized form 2 lg of total RNA using
M-MLV reverse transcriptase (Promega, Madison, WI,
USA) according to the manufacturer’s protocol. By using
the specific primer pairs described in Table 1 and SYBR
GREEN Premix (Toyobo, Japan), quantitative real-time
PCR (qPCR) was performed on the LightCycler 480 real-
time PCR system (Roche Diagnostics, Mannheim, Ger-
many). b-Actin was used as a housekeeping gene for nor-
malization, and a no template sample was used as a
negative control.
Statistical analysis
Statistical analysis was performed with SPSS 18.0 (SPSS
Inc., Chicago, IL, USA). Statistical comparisons for sig-
nificance were made with Wilcoxon signed-rank test for
paired samples. Differences between the groups were
analyzed statistically by using Student’s t test. The corre-
lations between DGCR8 and AGO2 expressions and clini-
copathologic parameters were assessed with the Pearson’s
correlation coefficient analysis. Generally, P value of
\0.05 was established to denote significance in all statis-
tical analyses performed in the study.
Results
Expression levels of DGCR8 and AGO2 mRNA
in colorectal cancer tissues and adjacent non-neoplastic
colorectal tissues of CRC patients
The mRNA expression levels of DGCR8 and AGO2 were
quantified by qPCR in paired specimens of human can-
cerous colorectal tissues and their respective non-neoplas-
tic colorectal tissues from 60 patients with CRC. The
DGCR8 and AGO2 mRNA levels were normalized to the
level of b-actin mRNA. Then, the qPCR data were ana-
lyzed by using DCT values [14]. Our study revealed that
DGCR8 mRNA expression was significantly higher in
carcinomatous tissues than in the corresponding non-
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neoplastic tissues in 44 of the 60 patients with CRC
(P \ 0.001; Fig. 1). However, AGO2 mRNA expression
was not significantly altered (P = 0.259, Fig. 2). The mean
value of DGCR8 mRNA expression level in cancerous
tissues was significantly higher than in non-neoplastic
colorectal tissues (P \ 0.001); however, the mean value of
AGO2 mRNA expression level was not different between
cancerous and non-neoplastic tissues (Fig. 3).
Relationship between DGCR8 and AGO2 mRNA
expression levels and the clinical parameters in patients
with CRC
The recent study demonstrated that AGO2 is not associated
with clinicopathological features, including patient age,
gender, and overall survival or tumor location, grade, stage,
and size, in CRC [7]. Therefore, we investigated whether
the mRNA expression levels of DGCR8 and AGO2 are
associated with any clinicopathologic parameters of CRC.
Prior to statistical analysis, raw qPCR data of DGCR8 and
AGO2 mRNA expression levels were normalized to ref-
erence gene, b-actin. Then, the qPCR data were analyzed
by the 2-DDCT method [14]. To evaluate the influence of
the clinical parameters on mRNA expression of DGCR8
and AGO2, patients were classified according to each
clinical characteristic. The clinicopathologic parameters in
60 patients (mean age: 63.6 ± 10.4 years) with CRC
according to DGCR8 and AGO2 mRNA expression levels
were presented in Table 2. Unfortunately, DGCR8 and
AGO2 mRNA expression levels were not statistically
associated with age, tumor stage (TNM), CEA titer, and
BMI clinical parameters in our CRC specimens. However,
higher mRNA expression level of DGCR8 was found in
higher group of AGO2 mRNA expression level, and vise
versa. Therefore, the mRNA expression levels of DGCR8
and AGO2 were positively correlated to each other.
Discussion
MicroRNA pathway is involved in the regulation of various
cellular processes, including cellular development, differ-
entiation, proliferation, cell death, metabolism, and carci-
nogenesis [4–6]. Deregulation of miRNAs in various
cancers may be related with altered expression and func-
tion of the genes involved in the miRNA machinery
components, including DGCR8 [13] and AGO2 [15].
The objectives of this study were to investigate the
mRNA expression levels of DGCR8 and AGO2 by RT-
qPCR method in pair-matched colorectal specimens and
Fig. 1 The relative DGCR8
mRNA level (normalized to the
corresponding b-actin mRNAs)
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analyze their correlation with different clinical character-
istics. We therefore identified the mRNA expression levels
of DGCR8 and AGO2 in CRC tissue compared with
adjacent non-neoplastic colorectal tissue in 60 patients with
CRC. We determined that DGCR8 mRNA expression level
was up-regulated in CRC. Just like the results of our
experiment, Sand et al. [8] demonstrated that DGCR8
mRNA expression level was up-regulated in epithelial skin
cancers. However, Shaikhibrahim et al. [12] showed also
its down-regulation in prostate cancer. DGCR8 is a
cofactor for Drosha, an RNAse III endonuclease, and also a
part of the microprocessor complex and has been found to
be essential for miRNAs maturation [10]. Drosha and
DGCR8 have evolved to regulate each other via a com-
plicated double-negative feedback circuit in which DGCR8
stabilizes Drosha through a direct interaction [16]. It thus
would be needed to assess the correlation between DGCR8
and Drosha mRNA expression levels in CRC cases.
Interestingly, we found the significant association between
DGCR8 and AGO2 mRNA expression levels in CRC. This
result suggested that DGCR8 and AGO2 may be associated
with colorectal carcinogenesis together.
Recently, rapidly accumulating evidence has been shown
that perturbation in miRNA biogenesis is closely associated
with development and progression of a variety of cancers,
including CRC [7, 17, 18]. As one of key enzymes in the
miRNA generating process, DICER and DROSHA have
been frequently studied [19–25]; however, there was a little
study about DGCR8 and AGO2 [8, 26]. Additionally,
DGCR8 and AGO2 mRNA expression levels analysis did
not even show any significant differences between malignant
melanomas (primary cutaneous malignant melanoma and
Fig. 2 The relative AGO2
mRNA level (normalized to the
corresponding b-actin mRNAs)





Fig. 3 Relative DGCR8 and AGO2 mRNA expression in CRC group
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cutaneous malignant melanoma metastases) and benign
melanocytic nevi [26]. Nevertheless, because DGCR8 and
AGO2 are two important components in miRNA maturation,
we investigated whether the altered mRNA expression levels
of DGCR8 and AGO2 are associated with the carcinogenesis
of CRC. As shown in Table 2, no association between altered
expressions of the two miRNA machinery components and
clinical parameters, including age, tumor stage, CEA titer,
and BMI, was revealed. Our result, in agreement with recent
study [7], showed no association between DICER, DRO-
SHA, and AGO2 and clinicopathological characteristics.
Due to a short follow-up period, we could not assess the
prognostic value of each miRNA machinery component in
our study group. Therefore, further investigation with longer
follow-up period will resume, and prognostic impact of the
components will be analyzed as soon as possible.
In this study, we investigated the mRNA expression
levels of two selected miRNA machinery components,
DGCR8 and AGO2, and their clinical association in CRCs
for the first time. Our data demonstrated that DGCR8 is
significantly up-regulated in CRC, suggesting that reduced
expression of DGCR8 may play an important role during
the process of colorectal carcinogenesis. Considering deep
correlation between DGCR8 and AGO2 in CRCs, further
study of these miRNA components should be needed in
various colorectal neoplastic regions.
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